메뉴 건너뛰기




Volumn 27, Issue 10, 2002, Pages 500-505

Current pharmacological treatment options for prostate cancer

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; AMINOGLUTETHIMIDE; ANTACID AGENT; ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CYPROTERONE ACETATE; DIETHYLSTILBESTROL; DOXORUBICIN; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE SODIUM; FINASTERIDE; FLUTAMIDE; GONADORELIN AGONIST; GOSERELIN; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOCONAZOLE; LEUPRORELIN; MEDROXYPROGESTERONE ACETATE; MEGESTROL ACETATE; MITOXANTRONE; NILUTAMIDE; PAMIDRONIC ACID; PREDNISONE; PROTON PUMP INHIBITOR; SILDENAFIL; TRIPTORELIN; UNINDEXED DRUG; VINBLASTINE; ZOLEDRONIC ACID;

EID: 0036821318     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (1)

References (31)
  • 1
    • 0003964361 scopus 로고    scopus 로고
    • American Cancer Society. Cancer Facts and Figures 2002. Available at: http://www.cancer.org/eprise/main/docroot/stt/stt_0. Accessed June 26, 2002.
    • (2002) Cancer Facts and Figures 2002
  • 2
    • 0012499220 scopus 로고    scopus 로고
    • Recognizing prostate cancer
    • Slovin SF. Recognizing prostate cancer. Fed Practitioner 2002(Suppl);5-6.
    • (2002) Fed Practitioner , Issue.SUPPL. , pp. 5-6
    • Slovin, S.F.1
  • 3
    • 0026444924 scopus 로고
    • TNM classification of prostate cancer
    • Schroder FH, Hermanek P, Denis L, et al. TNM classification of prostate cancer. Prostate 1992;(Suppl)4:129-138.
    • (1992) Prostate , vol.4 , Issue.SUPPL. , pp. 129-138
    • Schroder, F.H.1    Hermanek, P.2    Denis, L.3
  • 4
    • 0003452668 scopus 로고    scopus 로고
    • Philadelphia: Lippincott-Raven Publishers
    • th ed. Philadelphia: Lippincott-Raven Publishers; 1997.
    • (1997) th Ed.
    • Fleming, I.D.1
  • 5
    • 0012499221 scopus 로고    scopus 로고
    • Prostate cancer staging
    • Roth BJ. Prostate cancer staging. Fed Practitioner 2002(Suppl) 9-14.
    • (2002) Fed Practitioner , Issue.SUPPL. , pp. 9-14
    • Roth, B.J.1
  • 7
    • 0037068646 scopus 로고    scopus 로고
    • A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer
    • Holmberg L, Bill-Axelson A, Helgesen F, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002;347:781-789.
    • (2002) N Engl J Med , vol.347 , pp. 781-789
    • Holmberg, L.1    Bill-Axelson, A.2    Helgesen, F.3
  • 8
    • 0037068634 scopus 로고    scopus 로고
    • Quality of life after radical prostectomy or watchful waiting
    • Steineck G, Helgesen F, Adolfsson J, et al. Quality of life after radical prostectomy or watchful waiting. N Engl J Med 2002; 347:790-796.
    • (2002) N Engl J Med , vol.347 , pp. 790-796
    • Steineck, G.1    Helgesen, F.2    Adolfsson, J.3
  • 9
    • 0034763168 scopus 로고    scopus 로고
    • Counseling the patient with prostate cancer about treatment-related erectile dysfunction
    • Montorsi F, Salonia A, Zanoni M, et al. Counseling the patient with prostate cancer about treatment-related erectile dysfunction. Curr Opin Urol 2001;11:611-617.
    • (2001) Curr Opin Urol , vol.11 , pp. 611-617
    • Montorsi, F.1    Salonia, A.2    Zanoni, M.3
  • 10
    • 0030856678 scopus 로고    scopus 로고
    • Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
    • Bolla M, Gonzalez D, Warde P, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997;337:295-300.
    • (1997) N Engl J Med , vol.337 , pp. 295-300
    • Bolla, M.1    Gonzalez, D.2    Warde, P.3
  • 11
    • 85077295843 scopus 로고    scopus 로고
    • Triptorelin approved for prostate cancer treatment
    • Millar JL. Triptorelin approved for prostate cancer treatment. Am J Health Syst Pharm 2000;57:1386.
    • (2000) Am J Health Syst Pharm , vol.57 , pp. 1386
    • Millar, J.L.1
  • 12
    • 0031403675 scopus 로고    scopus 로고
    • Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
    • The Medical Research Council Prostate Cancer Working Party Investigators Group. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. Br J Urol 1997;79:235-246.
    • (1997) Br J Urol , vol.79 , pp. 235-246
  • 13
    • 0037072063 scopus 로고    scopus 로고
    • Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial
    • Bolla M, Collettee L, Blank L, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): A phase III randomised trial. Lancet 2002;360:103-108.
    • (2002) Lancet , vol.360 , pp. 103-108
    • Bolla, M.1    Collettee, L.2    Blank, L.3
  • 14
    • 0036112592 scopus 로고    scopus 로고
    • The current state of hormonal therapy for prostate cancer
    • Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. Cancer 2002;52:154-179.
    • (2002) Cancer , vol.52 , pp. 154-179
    • Hellerstedt, B.A.1    Pienta, K.J.2
  • 15
    • 0035046991 scopus 로고    scopus 로고
    • The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone-releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer
    • Tomera K, Gleason D, Gittelman M, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone-releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165:1585-1589.
    • (2001) J Urol , vol.165 , pp. 1585-1589
    • Tomera, K.1    Gleason, D.2    Gittelman, M.3
  • 16
    • 0001941191 scopus 로고    scopus 로고
    • Androgens
    • Hardman JG, Limbird LE, Molinoff PB, et al, eds. New York: McGraw-Hill
    • th ed. New York: McGraw-Hill, 1996;1441-1457.
    • (1996) th Ed. , pp. 1441-1457
    • Wilson, J.D.1
  • 17
    • 0024324367 scopus 로고
    • A controlled trial of leuprolide with and without flutamide in prostatic carcinoma
    • Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419-424.
    • (1989) N Engl J Med , vol.321 , pp. 419-424
    • Crawford, E.D.1    Eisenberger, M.A.2    McLeod, D.G.3
  • 18
    • 0034728828 scopus 로고    scopus 로고
    • Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials
    • Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials. Lancet 2000;355:1491-1498.
    • (2000) Lancet , vol.355 , pp. 1491-1498
  • 19
    • 0027477695 scopus 로고
    • Prostate-specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome
    • Kelly WK, Scher HI. Prostate-specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 1993;149:607-609.
    • (1993) J Urol , vol.149 , pp. 607-609
    • Kelly, W.K.1    Scher, H.I.2
  • 20
    • 8444251062 scopus 로고    scopus 로고
    • Prostate-specific antigen (PSA) best practice policy
    • American Urological Association. Prostate-specific antigen (PSA) best practice policy. Oncology 2000;14:267-286.
    • (2000) Oncology , vol.14 , pp. 267-286
  • 21
    • 0034651802 scopus 로고    scopus 로고
    • A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma
    • Dawson NA, Conaway M, Halabi S, et al. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. Cancer 2000;88:825-834.
    • (2000) Cancer , vol.88 , pp. 825-834
    • Dawson, N.A.1    Conaway, M.2    Halabi, S.3
  • 22
    • 0023726635 scopus 로고
    • Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies
    • Byar DP, Corle DK Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;7:165-170.
    • (1988) NCI Monogr , vol.7 , pp. 165-170
    • Byar, D.P.1    Corle, D.K.2
  • 23
    • 0035449137 scopus 로고    scopus 로고
    • Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate cancer outcomes study
    • Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: Results from the prostate cancer outcomes study. J Clin Oncol 2001;19:3750-3757.
    • (2001) J Clin Oncol , vol.19 , pp. 3750-3757
    • Potosky, A.L.1    Knopf, K.2    Clegg, L.X.3
  • 24
    • 0034015673 scopus 로고    scopus 로고
    • Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors
    • Moinpour CM, Lovato LC, Thompson IM, et al. Profile of men randomized to the prostate cancer prevention trial: Baseline health-related quality of life, urinary and sexual functioning, and health behaviors. J Clin Oncol 2000;18:1942-1953.
    • (2000) J Clin Oncol , vol.18 , pp. 1942-1953
    • Moinpour, C.M.1    Lovato, L.C.2    Thompson, I.M.3
  • 25
    • 0034490101 scopus 로고    scopus 로고
    • Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress?
    • Culine S, Droz JP. Chemotherapy in advanced androgen-independent prostate cancer 1990-1999: A decade of progress? Ann Oncol 2000;11:1523-1530.
    • (2000) Ann Oncol , vol.11 , pp. 1523-1530
    • Culine, S.1    Droz, J.P.2
  • 26
    • 0020956138 scopus 로고
    • Weekly doxorubicin in endocrine-refractory carcinoma of the prostate
    • Torti FM, Aston D, Lum BL, et al. Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1983;1:477-482.
    • (1983) J Clin Oncol , vol.1 , pp. 477-482
    • Torti, F.M.1    Aston, D.2    Lum, B.L.3
  • 27
    • 0028208515 scopus 로고
    • Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer
    • Moore MJ, Osoba D, Murphy K, et al. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer. J Clin Oncol 1994;12:689-694.
    • (1994) J Clin Oncol , vol.12 , pp. 689-694
    • Moore, M.J.1    Osoba, D.2    Murphy, K.3
  • 28
    • 0031042208 scopus 로고    scopus 로고
    • Estramustine-based chemotherapy
    • Hudes G. Estramustine-based chemotherapy. Semin Urol Oncol 1997;15:13-19.
    • (1997) Semin Urol Oncol , vol.15 , pp. 13-19
    • Hudes, G.1
  • 29
    • 0012605521 scopus 로고    scopus 로고
    • MedWatch 2002 Safety Information. Available at: http://www.fda.gov/medwatch/safety/2002/safety02.htm. Accessed July 11, 2002.
    • (2002) MedWatch 2002 Safety Information
  • 31
    • 0034834096 scopus 로고    scopus 로고
    • SELECT: The next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial
    • Klein EA, Thompson IM, Lippman SM, et al. SELECT: The next prostate cancer prevention trial. Selenium and Vitamin E Cancer Prevention Trial. J Urol 2001;166:1311-1315.
    • (2001) J Urol , vol.166 , pp. 1311-1315
    • Klein, E.A.1    Thompson, I.M.2    Lippman, S.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.